Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. John P. Shannon | CEO & Director | 918.15k | -- | 1962 |
| Mr. Steven M. Pieper | Chief Financial Officer | 681.14k | -- | 1977 |
| Ms. Beth P. Hecht J.D. | Chief Legal Officer & Corporate Secretary | 695.44k | -- | 1964 |
| Mr. Paul R. Edick J.D. | Senior Advisor | 1.21M | -- | 1956 |
| Dr. Kenneth E. Johnson Pharm. D., Pharm.D. | Senior VP of Global Development & Medical Affairs | 596.97k | -- | 1963 |
| Ms. Allison Wey | Senior Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Mr. Brian Conner | SVP of Quality and Chief Compliance & Risk Officer | -- | -- | -- |
| Ms. Kendal Korte | Senior Vice President of Human Resources | -- | -- | -- |
| Mr. Kevin McCulloch | Chief Commercial Officer | -- | -- | -- |
Xeris Biopharma Holdings, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 377
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Corporate Governance
Upcoming Events
March 4, 2025 at 12:00 PM UTC - March 8, 2025 at 12:00 PM UTC
Xeris Biopharma Holdings, Inc. Earnings Date
Recent Events
August 6, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
June 21, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission